Year: 2026
Type: article
Abstract: CD24 is a heavily glycosylated surface protein reportedly expressed across a broad range of solid and hematological malignancies, making it an attractive candidate antigen for chimeric antigen receptor (CAR) T-cell therapy. Using publicly available datasets, we confirmed that CD24 is broadly expressed across tumor types and, in a single CD19-negative relapse of B-cell acute lymphoblastic leukemia, remained expressed after CD19 CAR T-cell therapy. Thus, CD24 has potential both as a pan-cancer target and as a second-line or combinatorial target following antigen escape. Notably, the antigen recognition domain of the CAR, typically a single chain variable fragment (scFv) of an antibody, is a critical determinant of CAR specificity and function. We here, therefore, performed a head-to-head comparison of four CD24 second-generation 4-1BB CAR T-cells differing only in their scFv clone, specifically clones H2L3, SWA11 and GB7011–05 recognizing the protein core of CD24 and clone SN3 recognizing a CD24 glyco-epitope. The H2L3-derived CAR T-cells displayed high basal IFN-γ production whereas the SWA11-derived CAR T-cells were cytotoxic against cell lines with undetectable CD24 expression. The SN3- and GB7011–05 derived CARs were CD24-specific, and phenotypically equivalent, making them both promising candidates for further exploitation.
Source: Frontiers in Immunology
Authors: Maria Lysandrou(Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing), Jimena Álvarez Freile(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Writing – review & editing), Douwe Freerk Samplonius(Investigation, Methodology, Writing – review & editing), Edwin Bremer(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing)
Institutions: University Medical Center Groningen, University of Groningen
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235014821
